Egrifta (Tesamorelin) Standard Titration Schedule: A Women's Guide

What Is Tesamorelin and Why Does the Titration Matter for Women?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) secretion, which in turn raises insulin-like growth factor 1 (IGF-1) and drives visceral adipose tissue (VAT) reduction. The FDA approved Egrifta in 2010 for adults with HIV-associated lipodystrophy, but prescribers increasingly use it off-label for visceral adiposity linked to hormonal shifts in perimenopausal and postmenopausal women.

The titration question matters more for women than most prescribers acknowledge. Estrogen profoundly modifies GH secretion and IGF-1 sensitivity. Women generally have higher GH pulse amplitude than men at baseline, yet paradoxically, oral estrogen therapy suppresses hepatic IGF-1 production by up to 30 to 40 percent compared with transdermal estrogen, a difference documented by Weissberger et al. that has direct implications for dosing decisions. Starting too high, too fast can amplify fluid retention and arthralgias, side effects women already experience at higher rates than men in GH-axis drug trials.

The FDA Label Dose: No Formal Step-Up

The FDA-approved prescribing information for Egrifta states a single dose: 2 mg injected subcutaneously once daily. There is no multi-step titration schedule in the label itself. That simplicity, however, reflects trial design for a predominantly male HIV population, not a consideration of female sex-specific pharmacokinetics or tolerability.

Why Clinicians Use a 1 mg Starting Dose in Women

In practice, many women's-health and obesity medicine prescribers begin at 1 mg daily for the first two to four weeks, then advance to 2 mg if tolerability is good. The rationale:

• Women have higher baseline GH pulse amplitude and may be more sensitive to GHRH stimulation.
• Fluid retention and arthralgias, the most common tesamorelin side effects, are more pronounced in individuals with lower lean body mass relative to fat mass, a pattern common in postmenopausal women.
• IGF-1 overshoot above the upper limit of normal is a signal to reduce dose, and starting lower gives a wider safety margin before the first IGF-1 check at four weeks.

This 1-mg-then-2-mg approach is a clinical convention, not an evidence-based protocol derived from a dedicated female cohort trial. The data gap is real, and you deserve to know it.

The Standard Titration Schedule Step by Step

The schedule below reflects the FDA label as the foundation, with the real-world female-practice modification noted explicitly.

Weeks 1 Through 4: Initiation

FDA label: 2 mg subcutaneously once daily, starting on day 1.

Women's-practice modification: 1 mg subcutaneously once daily at bedtime. Bedtime dosing aligns the exogenous GHRH stimulus with the physiologic nocturnal GH surge, which occurs during slow-wave sleep, a timing convention supported by Van Cauter et al. and applied broadly in growth hormone axis therapies.

Rotate injection sites among the abdomen, outer thigh, and the area around the navel, staying at least 2 inches away from the navel itself. Do not inject into scars, bruises, or areas of active lipodystrophy.

At the end of week 4, check fasting IGF-1. If IGF-1 is within the age- and sex-adjusted normal range and tolerability has been acceptable, advance to 2 mg.

Weeks 5 Through 12: Target Dose

Advance to 2 mg subcutaneously once daily at bedtime. This is the therapeutic dose used in the key Falutz et al. NEJM 2007 trial, which enrolled 412 adults with HIV-associated lipodystrophy and demonstrated a statistically significant reduction in VAT of approximately 18 cm² more than placebo at week 26. The trial was not stratified by sex in a way that allows clean female-specific effect estimates, which is a meaningful limitation.

Recheck IGF-1 at week 8 (four weeks after reaching 2 mg). If IGF-1 exceeds the upper limit of the normal reference range for your age and sex, reduce back to 1 mg and recheck in another four weeks.

Week 12 and Beyond: Monitoring and Continuation

If IGF-1 remains in range and visceral adiposity reduction is the goal, continue 2 mg daily. The Falutz et al. NEJM 2007 trial showed that VAT reduction becomes statistically detectable by week 26, so short trials of less than six months are unlikely to show meaningful imaging change.

Obtain a follow-up DXA or abdominal CT/MRI to quantify VAT at six months if baseline imaging was done. Fasting glucose and HbA1c should be checked every three months, because tesamorelin can modestly raise fasting glucose through GH-mediated insulin resistance. The FDA label carries a warning about glucose monitoring precisely for this reason.

How Hormonal Life Stage Changes Your Tesamorelin Response

This framework is not in any single guideline or trial. It synthesizes what is known about female GH-axis physiology across life stages and applies it to tesamorelin dosing decisions. Consider it a clinical map, not established protocol.

Reproductive Years (Ages Roughly 18 to 44)

In ovulatory women, estrogen levels fluctuate with the menstrual cycle and peak in the follicular and preovulatory phases. Estrogen acutely increases GH pulse amplitude. This means tesamorelin's GHRH stimulus lands on a GH-pituitary axis that is already more responsive mid-cycle than in the luteal phase or during menses. Clinical significance is probably small at the 1-to-2 mg dose range, but IGF-1 drawn mid-cycle may read higher than one drawn in the luteal phase, so standardize your lab timing to the same cycle phase when possible.

Women of reproductive age are rarely candidates for tesamorelin under current FDA-approved indications. Off-label use for PCOS-associated visceral adiposity or metabolic dysfunction is theoretically plausible given that women with PCOS carry excess visceral fat independent of BMI, but no controlled trial has tested tesamorelin in a PCOS population. Prescribers considering it off-label in reproductive-age women must address contraception before starting (see Pregnancy section below).

Perimenopause (Typically Ages 45 to 55)

The perimenopause transition brings erratic estrogen surges and drops, rising FSH, and accelerating visceral fat accumulation even without significant weight gain. GH pulse amplitude and frequency decline in parallel with estrogen, a process that probably contributes to the VAT gain many perimenopausal women notice around the abdomen.

Tesamorelin is pharmacologically well-targeted to this biology: it restores GH pulsatility via pituitary stimulation rather than replacing GH directly, which carries a lower risk of GH excess. Clinically, perimenopausal women may see a more pronounced VAT response than older postmenopausal women because residual pituitary GH reserve is higher. However, this population has essentially no representation in published tesamorelin RCTs, and the data gap must be acknowledged plainly.

Postmenopause

After menopause, endogenous estrogen drops to very low levels unless hormone therapy is used. Postmenopausal GH pulse amplitude falls further, and somatotroph reserve declines. This means the pituitary has less capacity to respond to GHRH stimulation, so tesamorelin's efficacy may be attenuated compared with younger women.

The route of estrogen therapy also matters here. Women on oral estrogen have suppressed hepatic IGF-1 production compared with those on transdermal estrogen, as noted by Weissberger et al.. If you are on oral estradiol or conjugated equine estrogen and your IGF-1 response to tesamorelin is blunted at 2 mg, switching to a transdermal formulation (patch, gel, or spray) may improve the IGF-1 signal without changing the tesamorelin dose. Discuss this with your prescriber before making any changes to hormone therapy.

Dose Adjustments: When to Go Up, When to Back Down

Reasons to Reduce the Dose

• IGF-1 above the upper limit of the age- and sex-specific normal range on two consecutive checks.
• Persistent pitting edema of the ankles or hands that does not resolve after two weeks at the current dose.
• Moderate-to-severe joint pain or carpal tunnel symptoms that emerged after starting or after a dose increase.
• Fasting glucose above 126 mg/dL or HbA1c above 6.5% on two checks, at which point the prescriber must weigh risk and benefit carefully given the FDA warning.

In these situations, reduce to 1 mg daily (or to 0.5 mg if the 1-mg dose was already causing the problem) and recheck IGF-1 and fasting glucose in four weeks.

Reasons to Maintain at 2 mg

• IGF-1 in the normal range, no edema, no joint complaints, and fasting glucose unchanged or improved from baseline.
• Measurable VAT reduction by imaging at six months.
• Improved patient-reported outcome on truncal fullness or abdominal contour.

When to Discontinue

The FDA label does not specify a maximum treatment duration. The Falutz trial extension arm showed that VAT returns toward baseline within 12 weeks of stopping, which means tesamorelin requires ongoing use to maintain effect. If cost, tolerability, or another medical concern limits long-term use, a supervised taper is not pharmacologically necessary (GHRH analogues do not cause rebound suppression of the GH axis the way exogenous GH replacement does), but stopping abruptly will result in VAT re-accumulation over months.

Injection Technique: Women-Specific Notes

Subcutaneous fat distribution differs between women and men. Women carry more subcutaneous abdominal fat and have a thicker panniculus, which is not a barrier to drug delivery but does mean injection depth and needle angle matter. A 4-to-5 mm 31-gauge needle inserted at a 45-degree angle into pinched subcutaneous tissue delivers drug reliably without hitting muscle. A 90-degree angle works if you pinch the skin and the subcutaneous layer is at least 8 mm thick, which it usually is in women with abdominal adiposity.

Reconstitute Egrifta using the diluent provided by the manufacturer. The FDA label instructs you to swirl gently rather than shake, because tesamorelin is a peptide and shaking denatures it. Inject immediately after reconstitution or within three hours if kept at room temperature. Do not refrigerate the reconstituted solution.

Pregnancy, Lactation, and Contraception

Tesamorelin is absolutely contraindicated in pregnancy.

This is not a precautionary softening. The FDA label assigns tesamorelin to Pregnancy Category X (under the legacy classification system) based on animal reproductive toxicity data showing fetal harm. Human pregnancy data are absent because the drug is contraindicated, and no ethical trial will be conducted in pregnant women. If you could become pregnant, you must use reliable contraception throughout tesamorelin treatment and for at least one month after stopping.

Reliable Contraception Options While on Tesamorelin

Any highly effective method qualifies: combined hormonal pills, progestin-only pills, a hormonal or copper IUD, a subdermal implant, or injectable medroxyprogesterone. Barrier methods alone are not recommended given the Category X status.

What to Do If You Become Pregnant

Stop tesamorelin immediately. Contact your prescriber the same day. The risk to the fetus from ongoing exposure is unknown but the animal data mandate discontinuation without delay.

Lactation

Tesamorelin's transfer into human breast milk has not been studied. Given that tesamorelin is a peptide and that GH-axis hormones do transfer into milk to some degree, the conservative position is to avoid tesamorelin during breastfeeding. The FDA label advises against use in nursing mothers. If you are postpartum and interested in tesamorelin for metabolic reasons, discuss timing with your clinician and wait until breastfeeding is fully weaned.

Postpartum Thyroiditis Note

Postpartum thyroiditis affects approximately 5 to 10 percent of women in the first year after delivery, according to American Thyroid Association estimates. Untreated hypothyroidism blunts GH-axis responses and would reduce tesamorelin efficacy. Screen for thyroid dysfunction before starting tesamorelin in any postpartum woman, and recheck thyroid function if IGF-1 response is unexpectedly poor.

Who This Is Right For (and Who Should Not Take It)

Women Who Are Good Candidates

• Postmenopausal women with confirmed visceral adiposity (waist circumference above 88 cm or VAT above 100 cm² on imaging) who have not responded adequately to lifestyle modifications.
• Perimenopausal women with accelerating truncal adiposity and metabolic marker worsening (fasting insulin, triglycerides, SHBG) in whom GLP-1 receptor agonists are not tolerated or are contraindicated.
• Women with HIV-associated lipodystrophy, the only FDA-approved indication.
• Women with well-controlled type 2 diabetes whose glucose is monitored closely and whose HbA1c is below 8.0% at baseline.

Women Who Should Not Take Tesamorelin

• Anyone who is pregnant, trying to conceive, or not using reliable contraception.
• Women with active malignancy or a history of hormone-sensitive cancer, because IGF-1 is a mitogen and the potential for tumor promotion is a real biological concern.
• Women with pituitary disease or prior pituitary radiation, because the GHRH receptor target may be damaged.
• Women with severe fluid retention states: decompensated heart failure, nephrotic syndrome, or cirrhosis.
• Women with a known hypersensitivity to tesamorelin or mannitol (an excipient in the formulation).
• Women who are breastfeeding.

Monitoring Schedule Summary

| Timepoint | Lab or Assessment | |---|---| | Baseline | Fasting IGF-1, fasting glucose, HbA1c, thyroid function, lipid panel, abdominal imaging if available | | Week 4 | Fasting IGF-1, tolerability review, dose advance decision | | Week 8 | Fasting IGF-1 at full 2 mg dose | | Week 12 | Fasting glucose, HbA1c | | Week 26 | Fasting IGF-1, fasting glucose, HbA1c, repeat abdominal imaging | | Every 6 months ongoing | Full panel above, pregnancy status confirmation |

Evidence Gaps in Women: What We Know and What Is Extrapolated

Women were not the primary study population in tesamorelin trials. The Falutz et al. NEJM 2007 trial enrolled 412 participants with HIV-associated lipodystrophy, a population that was approximately 80 percent male, reflecting the demographics of the HIV epidemic at that time. The sex-disaggregated efficacy and safety data were not published as primary outcomes.

What is directly studied in women: essentially nothing in dedicated female cohorts for tesamorelin.

What is extrapolated from male or mixed data:

• The 2 mg therapeutic dose
• The 26-week timeline for VAT reduction
• The IGF-1 monitoring thresholds
• The glucose monitoring warning

What is inferred from female GH-axis physiology:

• The rationale for a lower starting dose in women
• The oral-versus-transdermal estrogen interaction with IGF-1
• The attenuation of efficacy in older postmenopausal women with low pituitary reserve

This degree of data extrapolation is the norm, not the exception, for women in metabolic drug trials. The NIH Sex as a Biological Variable policy requires sex-stratified analysis in funded research, but legacy data remain predominantly male-derived.

Drug Interactions Relevant to Women

Oral Estrogen and Cortisone

Oral estrogen therapy induces hepatic binding protein production and suppresses IGF-1 generation, which may blunt the measurable IGF-1 response to tesamorelin without necessarily reducing clinical VAT effect. Oral corticosteroids can suppress GH secretion and similarly attenuate response. Women on either of these medications should have IGF-1 checked at the low end of the expected range and not have doses escalated based solely on a low IGF-1 reading without clinical context.

Insulin and Oral Hypoglycemics

Tesamorelin modestly raises fasting glucose through GH-mediated insulin resistance. Women already on insulin or sulfonylureas may need dose adjustments. Women on metformin alone have a lower hypoglycemia risk, but fasting glucose should still be monitored at the intervals in the table above.

Thyroid Hormone Replacement

Untreated or undertreated hypothyroidism blunts the GH axis and reduces tesamorelin efficacy. Women on levothyroxine should ensure thyroid function is optimized before attributing a poor IGF-1 response to tesamorelin failure.

Practical Tips for Staying on Schedule

Tesamorelin requires daily injection, which is a real adherence challenge. A few things that actually help:

• Pair the injection with an existing bedtime ritual (brushing teeth, skincare routine) so it becomes automatic rather than a separate task.
• Keep the unmixed powder and diluent at room temperature for up to three months rather than refrigerating if daily preparation is easier at room temperature. Check your specific lot instructions.
• Use a small sharps container kept in a bathroom drawer rather than a distant closet, because distance reduces follow-through.
• Set a phone alarm labeled with a brief phrase that reminds you why you are doing this, not just a generic medication alert.

If you miss a dose, take it the next day at the usual bedtime. Do not double-dose. Missing one or two doses per month is unlikely to meaningfully reduce your 26-week outcome.